PL3886814T3 - Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie - Google Patents
Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanieInfo
- Publication number
- PL3886814T3 PL3886814T3 PL19824070.7T PL19824070T PL3886814T3 PL 3886814 T3 PL3886814 T3 PL 3886814T3 PL 19824070 T PL19824070 T PL 19824070T PL 3886814 T3 PL3886814 T3 PL 3886814T3
- Authority
- PL
- Poland
- Prior art keywords
- pharmaceutical preparation
- lipoic acid
- preparation containing
- solid pharmaceutical
- containing lipoic
- Prior art date
Links
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 title 1
- 235000019136 lipoic acid Nutrition 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
- 229960002663 thioctic acid Drugs 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
- A61K31/51—Thiamines, e.g. vitamin B1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7135—Compounds containing heavy metals
- A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201831044436 | 2018-11-26 | ||
| PCT/US2019/063135 WO2020112699A1 (en) | 2018-11-26 | 2019-11-26 | Solid pharmaceutical preparation containing lipoic acid and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3886814T3 true PL3886814T3 (pl) | 2025-04-07 |
Family
ID=68966006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL19824070.7T PL3886814T3 (pl) | 2018-11-26 | 2019-11-26 | Stały preparat farmaceutyczny zawierający kwas liponowy i jego zastosowanie |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US11986460B2 (pl) |
| EP (1) | EP3886814B1 (pl) |
| CN (1) | CN113164396B (pl) |
| AU (1) | AU2019386979B2 (pl) |
| BR (1) | BR112021008602A2 (pl) |
| MX (1) | MX2021005888A (pl) |
| PL (1) | PL3886814T3 (pl) |
| WO (1) | WO2020112699A1 (pl) |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0334340B1 (en) | 1988-03-23 | 1994-11-09 | Seiko Instruments Inc. | Optically switching ferroelectric liquid crystal light valve |
| DE4317646A1 (de) | 1993-05-27 | 1994-12-01 | Asta Medica Ag | Tabletten mit Thioctsäure und mindestens einer basischen Komponente |
| DE19705555A1 (de) | 1997-02-13 | 1998-08-20 | Ulrich Dr Posanski | Pharmazeutische Präparate der Thioctsäure zur oralen Anwendung |
| US6197340B1 (en) | 1998-05-28 | 2001-03-06 | Medical Research Institute | Controlled release lipoic acid |
| US20050085498A1 (en) * | 1998-05-28 | 2005-04-21 | Byrd Edward A. | Oral formulation of lipid soluble thiamine, lipoic acid, creatine derivative, and L-arginine alpha-ketoglutarate |
| DE19938098A1 (de) | 1999-08-12 | 2001-02-15 | Woerwag Pharma Gmbh & Co | Feste Arzneimittelformulierung mit hohem Gehalt an Thioctsäure (alpha-Liponsäure) |
| US6495177B1 (en) | 1999-08-13 | 2002-12-17 | Warner Chilcott Laboratories Ireland Limited | Orally dissolvable nutritional supplement |
| US20020102301A1 (en) | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
| WO2003079819A1 (en) * | 2002-03-27 | 2003-10-02 | Anglo French Drugs And Industries Ltd. | Dietary supplement composition and a process of manufacturing said composition |
| AU2002254546A1 (en) | 2002-04-03 | 2003-10-20 | Mitchell A. Avery | Lipoic acid analogs useful as provitamins and antioxidants |
| ATE514418T1 (de) | 2002-11-12 | 2011-07-15 | Elan Pharma Int Ltd | Rasch zerfallende feste darreichungsformen mit nichtbröseliger konsistenz und pullulan |
| US20050147620A1 (en) | 2004-01-05 | 2005-07-07 | Karl Bozicevic | Cinnamon formulation for reducing cholesterol and/or glucose levels |
| US8728535B2 (en) * | 2005-08-04 | 2014-05-20 | Vertical Pharmaceuticals, Llc | Nutritional supplement for use under physiologically stressful conditions |
| AU2007276874B2 (en) | 2006-07-28 | 2010-08-19 | Dr. Reddy's Laboratories Ltd. | Granular pharmaceutical compositions |
| EP2572705B1 (en) | 2007-10-01 | 2017-09-13 | Laboratorios Lesvi, S.L. | Orodispersible tablets |
| US20090270469A1 (en) | 2008-04-25 | 2009-10-29 | Auspex Pharmaceuticals, Inc. | Substituted oxazolidinones |
| KR101209319B1 (ko) | 2008-04-29 | 2012-12-06 | 한올바이오파마주식회사 | 안지오텐신-ⅱ-수용체 차단제를 포함하는 약제학적 제제 |
| US20100021573A1 (en) | 2008-07-22 | 2010-01-28 | Michael J Gonzalez | Compositions and methods for the prevention of cardiovascular disease |
| US8575218B2 (en) * | 2009-09-28 | 2013-11-05 | The University Of Kentucky Research Foundation | Thiol-containing compounds for the removal of elements from tissues and formulations therefor |
| TWI400089B (zh) | 2009-11-24 | 2013-07-01 | Nippon Soda Co | 羥烷基纖維素微粒子 |
| CA2784407A1 (en) | 2009-12-17 | 2011-07-14 | Cima Labs Inc. | Abuse-resistant formulations |
| IT1403587B1 (it) | 2010-12-17 | 2013-10-31 | Laborest Italia S P A | Composizione per il trattamento di disordini metabolici |
| US20130084272A1 (en) | 2011-09-29 | 2013-04-04 | Philippe Perrin | Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols |
| CA2854054C (en) | 2011-12-02 | 2020-05-12 | Pegasus Laboratories, Inc. | Amphipathic lipid-based sustained release compositions |
| EP2809316A1 (en) | 2012-01-31 | 2014-12-10 | Mahmut Bilgic | Synergisctic combination comprising a meglitinide derivative and lipoic acid |
| ITMI20120661A1 (it) | 2012-04-20 | 2013-10-21 | Giellepi S P A | Composizione per il trattamento delle neuropatie |
| ITMI20130349A1 (it) | 2013-03-07 | 2014-09-08 | Laborest Italia S P A | Composizione per uso nel trattamento della sindrome dell ovaio policistico |
| US20140271890A1 (en) | 2013-03-14 | 2014-09-18 | Thaer Ahmad | Controlled-release pharmaceutical composition |
| DK3006045T3 (en) | 2014-10-07 | 2017-07-17 | Cyprumed Gmbh | Pharmaceutical formulations for oral administration of peptide or protein drugs |
| US10588890B2 (en) | 2017-05-30 | 2020-03-17 | Biommunity, Inc. | Compositions and methods to regulate hormonal cascades in stress disorders |
| TWI751379B (zh) | 2017-09-21 | 2022-01-01 | 奧孟亞股份有限公司 | 用於遞送胜肽之藥物組合物 |
| WO2019087054A1 (en) | 2017-11-01 | 2019-05-09 | Zenvision Pharma Llp | Novel pharmaceutical composition comprising dpp-4 inhibitor, alpha-lipoic acid and vitamin b12 |
-
2019
- 2019-11-26 PL PL19824070.7T patent/PL3886814T3/pl unknown
- 2019-11-26 AU AU2019386979A patent/AU2019386979B2/en active Active
- 2019-11-26 EP EP19824070.7A patent/EP3886814B1/en active Active
- 2019-11-26 WO PCT/US2019/063135 patent/WO2020112699A1/en not_active Ceased
- 2019-11-26 BR BR112021008602-1A patent/BR112021008602A2/pt unknown
- 2019-11-26 MX MX2021005888A patent/MX2021005888A/es unknown
- 2019-11-26 CN CN201980077865.9A patent/CN113164396B/zh active Active
- 2019-11-26 US US16/695,710 patent/US11986460B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| MX2021005888A (es) | 2021-06-23 |
| EP3886814A1 (en) | 2021-10-06 |
| BR112021008602A2 (pt) | 2021-08-03 |
| EP3886814B1 (en) | 2025-02-19 |
| AU2019386979B2 (en) | 2023-03-16 |
| AU2019386979A1 (en) | 2021-04-29 |
| US11986460B2 (en) | 2024-05-21 |
| WO2020112699A1 (en) | 2020-06-04 |
| US20200163934A1 (en) | 2020-05-28 |
| CN113164396A (zh) | 2021-07-23 |
| CA3116354A1 (en) | 2020-06-04 |
| CN113164396B (zh) | 2023-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279464A (en) | Pharmaceutical formulation of odevixibat | |
| IL289925A (en) | Adenosine derivative and pharmaceutical composition comprising the same | |
| ZA202000439B (en) | Liposome compositions comprising weak acid drugs and uses thereof | |
| GB201620066D0 (en) | Solid Pharmaceutical dosage formulations and processes | |
| EP3706741A4 (en) | PHARMACEUTICAL COMPOSITION AND USE THEREOF | |
| IL280376A (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
| IL273339A (en) | Griseofulbin compound and its medical use | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| EP3297640A4 (en) | Pharmaceutical co-crystal composition and use thereof | |
| SG11202010124SA (en) | Stable pharmaceutical formulation | |
| IL272806B1 (en) | The history of boronic acid, its preparation and pharmaceutical preparations containing it | |
| IL276311A (en) | Methyllactam ring compound and its pharmaceutical use | |
| ZA202006570B (en) | Pharmaceutical formulations | |
| SG10202008700VA (en) | α-TRUXILLIC ACID DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS THEREOF | |
| IL276323A (en) | 4-Methyldihydropyrimidinone compounds and their pharmaceutical use | |
| IL276430A (en) | A pharmaceutical compound, its cures, its formulations, and methods for its preparation and use | |
| PL3326619T3 (pl) | Stałe doustne kompozycje farmaceutyczne zawierające tenofowir i emtrycytabinę | |
| ZA202001174B (en) | Pharmaceutical compositions containing hyaluronic acid and carnosine and relative use | |
| IL281217A (en) | Pharmaceutical composition for controlled release of weak acid drugs and uses thereof | |
| EP3497080A4 (en) | PHARMACEUTICAL FORMULATIONS AND THEIR USE | |
| GB2595406B (en) | Pharmaceutical composition containing acetominophen and ibuprofen | |
| ZA201804275B (en) | Oral pharmaceutical composition comprising taste-masked n-acetylcysteine | |
| GB201721604D0 (en) | An oral liquid pharmaceutical composition of lamotrigine` | |
| PT3646864T (pt) | Medicamento contendo pemafibrato | |
| ZA202006346B (en) | Pharmaceutical preparation |